Gluten in pharmaceutical products: a scoping review

dc.contributor.author
Lizano Díez, Irene
dc.contributor.author
Mariño Hernández, Eduardo L.
dc.contributor.author
Modamio Charles, Pilar
dc.date.accessioned
2026-01-28T00:02:32Z
dc.date.available
2026-01-28T00:02:32Z
dc.date.issued
2026-01-27T09:05:37Z
dc.date.issued
2026-01-27T09:05:37Z
dc.date.issued
2021
dc.date.issued
2026-01-27T09:05:37Z
dc.identifier
2046-4053
dc.identifier
https://hdl.handle.net/2445/226210
dc.identifier
717571
dc.identifier.uri
https://hdl.handle.net/2445/226210
dc.description.abstract
Celiac disease (CD) is one of the most common gluten-related disorders. Although the only effective treatment is a strict gluten-free diet, doubts remain as to whether healthcare professionals take this restriction into consideration when prescribing and dispensing medicines to susceptible patients. This scoping review aimed to find out the current evidence for initiatives that either describe the gluten content of medicines or intend to raise awareness about the risk of prescribing and dispensing gluten-containing medicines in patients with CD and other gluten-related disorders.</p><p><br /></p><h3>Methods</h3><p>A scoping review was conducted using three search strategies in PubMed/MEDLINE, TripDatabase and Web of Science in April 2021, following the PRISMA extension for scoping reviews (PRISMA-ScR). References from included articles were also examined. Two researchers screened the articles and results were classified according to their main characteristics and outcomes, which were grouped according to the PCC (Population, Concept and Context) framework. The initiatives described were classified into three targeted processes related to gluten-containing medicines: prescription, dispensation and both prescription and dispensation.</p><p><br /></p><h3>Results</h3><p>We identified a total of 3146 records. After the elimination of duplicates, 3062 articles remained and ultimately 13 full texts were included in the narrative synthesis. Most studies were conducted in the US, followed by Canada and Australia, which each published one article. Most strategies were focused on increasing health professional’s knowledge of gluten-containing/gluten-free medications (<em>n</em> = 8), which were basically based on database development from manufacturer data. A wide variability between countries on provided information and labelling of gluten-containing medicines was found.</p><p><br /></p><h3>Conclusion</h3><p>Initiatives regarding the presence of gluten in medicines, including, among others, support for prescribers, the definition of the role of pharmacists, and patients’ adherence problems due to incomplete labelling of the medicines, have been continuously developed and adapted to the different needs of patients. However, information is still scarce, and some aspects have not yet been considered, such as effectiveness for the practical use of solutions to support healthcare professionals.
dc.format
12 p.
dc.format
application/pdf
dc.language
eng
dc.relation
Reproducció del document publicat a: https://doi.org/10.1186/s13643-021-01772-9
dc.relation
2021, vol. 10, num.1, p. 218
dc.relation
https://doi.org/10.1186/s13643-021-01772-9
dc.rights
cc-by-nc-nd (c) Lizano-Díez, I. et al., 2021
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Excipients
dc.subject
Medicaments
dc.subject
Dieta sense gluten
dc.subject
Malaltia celíaca
dc.subject
Malalties del tracte gastrointestinal
dc.subject
Excipients
dc.subject
Drugs
dc.subject
Gluten-free diet
dc.subject
Celiac disease
dc.subject
Gastrointestinal system diseases
dc.title
Gluten in pharmaceutical products: a scoping review
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.